bioverativ inc american multinational biotechnology company specializes discovery development delivery therapies treatment bioverativ competes baxalta acquired shire plc pfizer novo company traded nasdaq exchange ticker symbol bivv sanofi completed acquisition march may biogen announced would spin hemophilia drug business eloctate alprolix separate public august biogen announced would call spun company bioverativ show heritage would spun early december securities exchange commission approved bioverativs registration statement official separation date two companies pegged february february biogen investors received special dividend one share bioverativ stock every two shares biogen stock held january bioverativ began trading january may company announced would acquire true north therapeutics million strengthening bioverativs pipeline acquisition treatment cold agglutinin january sanofi announced would acquire business following illustration companys major mergers acquisitions historical predecessors true north therapeuticsacq bioverativ spun biogen company two current products alprolix eloctate products provided combined revenues million million first nine months contributing biogens total products marketed united states european union japan canada httpsenwikipediaorgwikibioverativ